Navigation Links
Perrigo Announces Final FDA Approval of Dexcel's OTC Omeprazole; Raises Full Year Earnings Guidance
Date:12/10/2007

ALLEGAN, Mich., Dec. 10 /PRNewswire-FirstCall/ -- The Perrigo Company (Nasdaq: PRGO; TASE) announced today that the U.S. Food & Drug Administration (FDA) has granted final approval to Dexcel Pharma Technologies, Ltd. for 20 mg Omeprazole delayed-release tablets. As the exclusive marketer and distributor of this product for the store brand over-the-counter (OTC) market in the United States, Perrigo expects to begin shipping its product during the first quarter of calendar year 2008, with full year annual sales to be in the range of $150 - $200 million.

Perrigo's Chairman and CEO Joseph C. Papa stated, "The approval from the FDA is the final regulatory step for this exclusive product launch, which we expect to be the largest product in Perrigo's 120 year history. While we are excited about the opportunity, we will obviously continue investing in research and development to add more new products to our product offering. The launch of Omeprazole is another example of Perrigo's dedication to make quality healthcare more affordable."

Based on pre-launch estimates, Perrigo's Omeprazole product is expected to contribute between $0.20 and $0.25 earnings per share in fiscal year 2008. As a result of the Omeprazole launch, full year earnings for fiscal year 2008 are expected to be in the range of $1.32 to $1.47 per share.

Prilosec OTC(R) is indicated for the treatment of frequent heartburn and had estimated current annual sales of approximately $750 million in all outlets.

Headquartered in Or Akiva, Israel, Dexcel Pharma Technologies, Ltd. is a privately-held, international specialty pharmaceutical company which focuses on the development, manufacture and marketing of innovative prescription, generic prescription, and OTC
'/>"/>

SOURCE The Perrigo Company
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related biology technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 26
3. Emisphere Technologies, Inc. Announces Pricing of Registered Direct Offering
4. BioLife Solutions Announces Exclusive CryoStor(TM) Supply Agreement With the New England Cryogenic Center, Inc.
5. Carrington Announces Nasdaq Communication; Prepares for Shares to Be Quoted on the OTC Bulletin Board and Pink Sheets
6. China Kangtai Cactus Biotech Files 2nd Quarter 2007 10QSB and Announces Unaudited Quarterly Results
7. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
8. Advanced Life Sciences Announces Receipt of Nasdaq Staff Letter
9. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
10. Angiotech announces additional diameters of sutures to further expand its Quill(TM) SRS PDO product line
11. CNS Response Announces Fiscal Third Quarter 2007 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2013)... a new study led by George Washington University ... nucleation of ice in small droplets is strongly ... at the nanoscale. The formation of ice at ... question whose answer also has important implications for ... crystallization of ice from supercooled water is generally ...
(Date:5/21/2013)... Raleigh, NC (PRWEB) May 21, 2013 ... and financial services company for clinical trials, announced ... Aggregate Spend Solutions, LLC. Clinverse’s ClinPay® FLS ... automated investigator payment process. SpendMD ™, ... only complete solution for tracking and reporting transfer ...
(Date:5/21/2013)... Many have long discussed the link between mental ... from Clinical Psychiatry.com readdressed the topic of ... suggested using hypnotherapy and other mental health ... that cause acne. , Doctors in the article mentioned ... stress causes changes in the skin that have been ...
(Date:5/21/2013)... May 21, 2013  Personal Genome Diagnostics Inc. ... proprietary methodologies and expertise in genomic analysis of ... in collaboration with Blueprint Medicines.  PGDx is an ... genomic alterations in tumors, and Blueprint Medicines is ... for a genetically defined patient population. ...
Breaking Biology Technology:Study led by GW professor provides better understanding of water's freezing behavior at nanoscale 2Clinverse, Inc. Announces Strategic Alliance with Aggregate Spend Solutions, LLC 2Clinverse, Inc. Announces Strategic Alliance with Aggregate Spend Solutions, LLC 3Adult Acne Treatment, Probiotic Action Explains How Hypnotherapy and Probiotics May Cure Various Skin Conditions 2Personal Genome Diagnostics And Blueprint Medicines Form Collaboration to Identify Novel Kinase Targets 2Personal Genome Diagnostics And Blueprint Medicines Form Collaboration to Identify Novel Kinase Targets 3
... GlaxoSmithKline CEO, described the pharmaceutical group,s results as,"robust" in a ... GSK also announced that it will cease ... goals. , Describing 2008 as a ... make very clear what it would take to really make ...
... BETHESDA, Md., Feb. 5 Micromet, Inc. (Nasdaq: MITI ), ... at the BIO CEO and Investor Conference at the Waldorf-Astoria in New ... presentation will be available on the company,s website at www.micromet-inc.com ., ... Date: Tuesday, February 10, 2009, ...
... type 2 diabetes enters clinical developmentCARLSBAD, Calif., Feb. 5 ... announced today it has initiated a Phase 1 study ... of sodium dependent glucose co-transporter type 2 (SGLT2). ... in the kidney. Decreasing SGLT2 levels promotes glucose ...
Cached Biology Technology:Micromet to Present at the BIO CEO and Investor Conference on February 10, 2009 2Micromet to Present at the BIO CEO and Investor Conference on February 10, 2009 3Micromet to Present at the BIO CEO and Investor Conference on February 10, 2009 4Isis Initiates Phase 1 Clinical Trial of SGLT2 Antisense Drug 2Isis Initiates Phase 1 Clinical Trial of SGLT2 Antisense Drug 3Isis Initiates Phase 1 Clinical Trial of SGLT2 Antisense Drug 4
(Date:5/21/2013)... modifications, which alter the way genes function without ... detected in the blood of pregnant women during ... foretell depression in the weeks after giving birth, ... debilitating. , The findings of the small study ... the journal Molecular Psychiatry . , "Postpartum ...
(Date:5/20/2013)... New research suggests that a compound abundant in the ... death. , By altering a very specific step ... into normal cells that die as scheduled. , One ... process that would cause them to die on a ... study in cells, led by Ohio State University researchers, ...
(Date:5/19/2013)... novel study reports that white men and women of ... (hallux valgus) and lesser toe deformities, including hammer or ... to estimate the heritability of foot disorders in humansappear ... published by Wiley on behalf of the American College ... as many as 60% of older adults have foot ...
Breaking Biology News(10 mins):Genetic predictors of postpartum depression uncovered by Hopkins researchers 2Genetic predictors of postpartum depression uncovered by Hopkins researchers 3The compound in the Mediterranean diet that makes cancer cells 'mortal' 2The compound in the Mediterranean diet that makes cancer cells 'mortal' 3Blame your parents for bunion woes 2
... American Geological Institute (AGI), in conjunction with its ... Needs for the Twenty First Century: The Role ... directions for the next President, his administration, federal ... identifies seven national issues and the role geosciences ...
... spiders are voracious predators and consume a wide range of ... have been proposed for why females eat males before or ... University in Ohio found, in a study published in the ... answer may be simpler than previously thought. Males are more ...
... A Florida State University researcher who uses high-powered computers ... mechanism that gives scientists a better understanding of how ... understanding eventually could lead to the development of new ... an assistant professor in FSU,s Department of Chemistry and ...
Cached Biology News:In spiders, size matters: Small males are more often meals 2Computational biochemist uncovers a molecular clue to evolution 2Computational biochemist uncovers a molecular clue to evolution 3
Rabbit polyclonal to NMDAR1 e/f/g/h ( Abpromise for all tested applications)....
Biotin anti-mouse Ly-49C/F/I/H...
Monoclonal Antibody to GLP Immunogen: Ni-NTA purified truncated recombinant GLP expressed in E. Coli strain BL21 (DE3)...
... Vitro Transcription Kits synthesize RNA probes with ... cpm/g. High specific activity, single-stranded RNA ... in situ hybridization, and blot hybridizations. MAXIscript ... synthesis of modest amounts of unlabeled RNA ...
Biology Products: